WHO Raises Alert Over Critical Scarcity of Obesity Medications
Fewer than 10% of individuals who could benefit from GLP-1 drugs such as Wegovy can access them, warns the WHO as it issues its inaugural guidance on the medications.
With over a billion individuals worldwide now obese, it is advocating for increased and just access to this class of drugs.
According to projections, over two billion could be obese by 2030 without intervention.
"Our new guidance acknowledges that obesity is a long-term condition that can be treated with holistic and continuous care," remarked its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and distribution challenges are significant obstacles to widespread access to the jabs that can assist patients in reducing substantial weight, explains the organization.
Skinny Jab Supply Crisis
Even under the present most optimistic outlook, the manufacturing of GLP-1 therapies could only cover around 100 million people – less than 10% of the global need, according to the WHO.
The guideline urges countries and companies to widen access, through approaches such as patent sharing.
The intellectual property rights on the active ingredient – the primary ingredient of Novo Nordisk's Wegovy – is scheduled to end in several nations in 2026.
How Obesity Injections Function
These medications replicate a biological compound to delay gastric emptying, suppress the appetite and increase feelings of fullness so users consume fewer calories.
Individuals usually see weight reduction within a few weeks of commencing the weekly injections.
Studies indicates patients may regain a significant portion within a year of halting the drug, because their usual hunger return.
Being overweight or obese increases your risk for experiencing medical conditions, like diabetes, heart disease, brain attack, and certain cancers.
Obesity impacts individuals in countries worldwide and was associated with millions of fatalities worldwide in 2024, according to the WHO.
